This is a good read from a trial participant.

Thumbs up for Nilotinib - Phase II Tr... - Parkinson'''s Movement

Conclusion: Nilotinib is well tolerated and appears to be safe in PD patients. Nilotinib appears to stop the decline in motor and non-motor functions when the effects of PD medications wear off six months after treatment. Nilotinib may have a significant impact on the care and management of PD patients, leading to delay or elimination of dose adjustment, thus avoiding various side effects associated with PD medications.

150mg dose did better than the 300mg dose